Neurocognitive profiles in MSUD school-age patients

[1]  Ryan J. McGill,et al.  Critical Issues in Specific Learning Disability Identification , 2016 .

[2]  F. Dal-Pizzol,et al.  Cerebral Oedema, Blood–Brain Barrier Breakdown and the Decrease in Na+,K+-ATPase Activity in the Cerebral Cortex and Hippocampus are Prevented by Dexamethasone in an Animal Model of Maple Syrup Urine Disease , 2016, Molecular Neurobiology.

[3]  C. Hollak,et al.  Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study , 2016, Journal of Inherited Metabolic Disease.

[4]  F. Chiarotti,et al.  Neurocognitive and neuroimaging outcome of early treated young adult PKU patients: A longitudinal study. , 2015, Molecular genetics and metabolism.

[5]  D. Brandeis,et al.  Erratum: Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinicaland neuropsychological outcomes from randomized controlled trials (Journal of the American Academy of Child and Adolescent Psychiatry (2015) 54 (164-174)) , 2015 .

[6]  M. Bjørås,et al.  Genome instability in Maple Syrup Urine Disease correlates with impaired mitochondrial biogenesis. , 2014, Metabolism: clinical and experimental.

[7]  Rani H. Singh,et al.  Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. , 2014, Molecular genetics and metabolism.

[8]  R. Blakely,et al.  Good riddance to dopamine: Roles for the dopamine transporter in synaptic function and dopamine-associated brain disorders , 2014, Neurochemistry International.

[9]  A. Sitta,et al.  Neurological Damage in MSUD: The Role of Oxidative Stress , 2014, Cellular and Molecular Neurobiology.

[10]  N. McNaughton,et al.  A comparison of phenylketonuria with attention deficit hyperactivity disorder: Do markedly different aetiologies deliver common phenotypes? , 2013, Brain Research Bulletin.

[11]  A. Stringer,et al.  Maple Syrup Urine Disease (MSUD): A Case with Long-Term Follow-up after Liver Transplantation , 2013, The Clinical neuropsychologist.

[12]  M. Walterfang,et al.  The neuropsychiatry of inborn errors of metabolism , 2013, Journal of Inherited Metabolic Disease.

[13]  E. Puffenberger,et al.  Maple Syrup Urine Disease , 2013 .

[14]  G. Moore,et al.  Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. , 2013, The Journal of clinical investigation.

[15]  G. Pentang,et al.  Structural white matter changes in adolescents and young adults with maple syrup urine disease , 2013, Journal of Inherited Metabolic Disease.

[16]  J. Lazovic,et al.  Interrupting the mechanisms of brain injury in a model of maple syrup urine disease encephalopathy , 2012, Journal of Inherited Metabolic Disease.

[17]  K. Walsh,et al.  Neurocognitive Profile in a Case of Maple Syrup Urine Disease , 2010, The Clinical neuropsychologist.

[18]  M. Welsh,et al.  Twenty-Five Years of Research on Neurocognitive Outcomes in Early-Treated Phenylketonuria: Intelligence and Executive Function , 2008, Developmental neuropsychology.

[19]  G. Homanics,et al.  Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease , 2008, Brain : a journal of neurology.

[20]  S. Wood,et al.  Are Neuropsychological Impairments in Children with Early-Treated Phenylketonuria (PKU) Related to White Matter Abnormalities or Elevated Phenylalanine Levels? , 2007, Developmental neuropsychology.

[21]  M. Watford.  Lowered concentrations of branched-chain amino acids result in impaired growth and neurological problems: insights from a branched-chain alpha-keto acid dehydrogenase complex kinase-deficient mouse model. , 2007, Nutrition reviews.

[22]  U. Langenbeck,et al.  Variant maple syrup urine disease (MSUD)—The entire spectrum , 2006, Journal of Inherited Metabolic Disease.

[23]  S. Schönberger,et al.  Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. , 2004, Molecular genetics and metabolism.

[24]  M. Wajner,et al.  Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease. , 2003, Biochimica et biophysica acta.

[25]  J. Haselgrove,et al.  Diffusion-weighted imaging in acute bacterial meningitis in infancy , 2003, Neuroradiology.

[26]  K. Strauss,et al.  Branched-chain ketoacyl dehydrogenase deficiency: Maple syrup disease , 2003, Current treatment options in neurology.

[27]  P. Kaplan,et al.  MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation , 2003, Neuroradiology.

[28]  E. Puffenberger,et al.  Diagnosis and treatment of maple syrup disease: a study of 36 patients. , 2002, Pediatrics.

[29]  D. Chuang,et al.  Maple syrup urine disease: it has come a long way. , 1998, The Journal of pediatrics.

[30]  U. Wendel,et al.  Intellectual performance of children with maple syrup urine disease , 1993, European Journal of Pediatrics.

[31]  C. Greene,et al.  Developmental profile of patients with maple syrup urine disease , 1991, Journal of Inherited Metabolic Disease.

[32]  P. Kaplan,et al.  Intellectual outcome in children with maple syrup urine disease. , 1991, The Journal of pediatrics.

[33]  Kenneth A. Kavale,et al.  A Meta-Analysis of the Validity of Wechsler Scale Profiles and Recategorizations: Patterns Or Parodies? , 1984 .

[34]  A. Rupp,et al.  Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria , 2009, European Journal of Pediatrics.

[35]  U. Wendel,et al.  Impact of Longitudinal Plasma Leucine Levels on the Intellectual Outcome in Patients with Classic MSUD , 2006, Pediatric Research.